RecruitingNot ApplicableNCT07632196

Efficacy and Safety of Transcutaneous Posterior Tibial Nerve Stimulation on Fecal Continence in Patients Undergoing Surgery for Rectal Neoplasia

Randomized Clinical Trial Assessing the Efficacy and Safety of Transcutaneous Posterior Tibial Nerve Stimulation on Fecal Continence in Patients Undergoing Surgery for Rectal Neoplasia

Sponsor

Althaia Xarxa Assistencial Universitària de Manresa

Enrollment

84 participants

Start Date

Feb 6, 2026

Study Type

INTERVENTIONAL

Conditions

Quality of Life (QOL)Rectal Neoplasm Malignant Fecal Incontinence (FI)Low Anterior Resection Syndrome (LARS)Disorder of Ejaculation

Summary

Rectal neoplasia is one of the most prevalent cancers in Spain, and the treatment of choice is total mesorectal excision (TME), as it has demonstrated significant oncological improvements. However, mesorectal excision is not without complications, and patients often experience altered bowel function in the form of low anterior resection syndrome (LARS), as well as erectile dysfunction. However, few studies evaluate faecal incontinence, as most focus on oncological outcomes. The aim of our study is to evaluate the efficacy and safety of posterior tibial nerve stimulation on fecal incontinence, sexual dysfunction, and quality of life in patients who underwent to rectal surgery for rectal neoplasia. It will be conducted a randomized clinical trial (1:1) with two arms: half of the patients will receive posterior tibial nerve stimulation, while the other half will undergo stimulation with subtherapeutic doses. Faecal incontinence will be assessed using the LARS and Wexner questionnaires, and quality of life and sexual function will be assessed using the Fecal Incontinence Quality of Life Scale (FIQLS) and the Colorectal Cancer Quality of Life Questionnaire (QLQ-CR38), at one month, six months and one year after surgery.

Eligibility

Min Age: 18 Years

Inclusion Criteria1

\- Adult patients diagnosed with rectal neoplasia and who have undergone a high anterior rectal resection regardless of the surgical approach (open, laparoscopic, laparoscopic+TaTME or robotic+TaTME).

Exclusion Criteria11

Patients not operated or within active surveillance strategy programs (watch \& wait)
Patients with ostomy
Patients with contraindications to the use of the neurostimulator:
Pacemaker / Defibrillator / Other electronic devices
History of heart problems
Propensity to excessive bleeding (coagulopathies)
Damage to the nervous system (epilepsy)
Current pregnancy
Infections or skin lesions
Severe vascular disorders
Active neoplasms.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEPosterior tibial nerve stimulation intervention group

In the intervention group, Beurer EM-49 digital neurostimulator will be used, with CE marking, and a dose of 20 Hertz (Hz) - 200 microseconds (μs) will be applied. As the control group and the intervention group, the pelvic floor rehabilitator will program the neurostimulator for each case and then they will be trained on how to perform the neurostimulation. The first session will be carried out with the rehabilitator to learn how it works and resolve doubts about its use, and later the sessions will be carried out at home. In both groups, a program for carrying out sessions will be indicated according to the following scheme: * From the 1st month to the 3rd month post-surgery: stimulation 3 times a week * From the 4th month to the 6th month post-surgery: stimulation 2 times a week * From the 7th to the 12th month post-surgery: 1 time a week

DEVICEControl group

In the intervention group, Beurer EM-49 digital neurostimulator will be used, with CE marking; and a dose of 80 Hertz (Hz) - 150 microseconds (μs) will be applied. As the control group and the intervention group, the pelvic floor rehabilitator will program the neurostimulator for each case and then they will be trained on how to perform the neurostimulation. In order to apply the therapy, the patient must sit down for the placement of the electrodes. It will be performed on 2 feet at the same time. The first session will be carried out with the rehabilitator to learn how it works and resolve doubts about its use, and later the sessions will be carried out at home. In both groups, a program for carrying out sessions will be indicated according to the following scheme: * From the 1st month to the 3rd month post-surgery: stimulation 3 times a week * From the 4th month to the 6th month post-surgery: stimulation 2 times a week * From the 7th to the 12th month post-surgery: 1 time a week